Do you want to read an article? Please log in or register.
Multicenter Real-World Data on First-Line Chemoimmunotherapy in Patients With Advanced Non-Small Cell Lung Cancer and Performance Status 2: WJOG18424L
Lung Cancer
Related content
Lung Cancer
Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS)
Clin Lung Cancer
Sakata Y, Saito G, Sakata S, Yamaguchi T, Tamiya M, Suzuki H, Shibaki R, Okada A, Yokoyama T, Matsumoto H, Otsuki T, Sato Y, Uchida J, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T
doi: 10.1016/j.cllc.2025.05.015
Lung Cancer
A Patient-Centric, Open-Label, Multicenter, Phase II Study of Lorlatinib Monotherapy in the First-Line Treatment of Patients With locally Advanced or Metastatic ALK-Positive Non-Small Cell Lung Cancer (CTONG2203)
Clin Lung Cancer
Lin JX, Zhou Q, Yan HH, Liu AW, Wu GW, Chu Q, Du YY, Cui JW, Cheng Y, Yang Y, Xu HP, Tu HY, Wu YL, Liu SM
doi: 10.1016/j.cllc.2025.05.014
Lung Cancer
Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancer
Sci Rep
Shin JE, Jung HA, Park S, Sun JM, Lee SH, Ahn JS, Ahn MJ, Shim BY
doi: 10.1038/s41598-024-81704-4
Lung Cancer
Real-World Effectiveness of Second-Line Therapies in Advanced Non-Small Cell Lung Cancer: Insights From Propensity-Weighted Comparative Analyses of Longitudinal EHR Data
Clin Lung Cancer
Hettinger GCN, Long Q, Parikh RB
doi: 10.1016/j.cllc.2025.09.010
Lung Cancer
Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States
Adv Ther
Sankar K, Unni S, Eberl M, Le H, Herrmann T, Gorsh B, Tang M, Coerts F, Ahmed S
doi: 10.1007/s12325-025-03408-z
Lung Cancer
Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non-small cell lung cancer treated with first-line ALK tyrosine kinase inhibitors
Lung Cancer
Liu G, Abrahami D, Ramachandran P, Messina R, Rifi N, Yang H, Chai X, Li B, Ramaswamy K, Iyengar P, Pennell NA, Shaw AT
doi: 10.1016/j.lungcan.2025.108858
RECOMMENDED
Lung Cancer
Impact of Incidental Germline BRCA1/2 and PALB2 Alterations on EGFR Monotherapy Real-World Outcomes for Patients With Advanced Non-Small-Cell Lung Cancer
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Clin Lung Cancer
Vakkalagadda CV, Bucheit L, Clemens K, Saha J, Zhang N, Patel JD
doi: 10.1016/j.cllc.2025.07.007
Further Publications
Neoadjuvant chemoimmunotherapy in non-small-cell lung cancer patients: Effects on pulmonary function and incidence of postoperative pulmonary complications-a multicenter real-world study
Eur J Cardiothorac Surg
Zhang J, Feng Y, Dai S, Xu G, Cheng B, Jiang L, Xue LP, Liang W, Tang J
doi: 10.1093/ejcts/ezaf351
RECOMMENDED
Lung Cancer
Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Front Oncol
Justeau G, Chouaid C, Debieuvre D, Audigier-Valette C, Quantin X, Léna H, Bosquet L, Girard N, Schoemaker MJ, Mella M, Pinto Correia B, Rault C, Daumont MJ, Penrod JR, Lee A, Pérol M
doi: 10.3389/fonc.2025.1526931